What’s Actually Happening With the New EDS Diagnostic Criteria?

Minimalist sketch of six people looking in different directions beneath floating question marks, drawn in soft gray and pale blue on a white background.


If you think the goalpost for the announcement of the new criteria for hEDS has moved, please know you were not hallucinating. It has. This past week, the EDS Society officially announced that The Road to 2026 special edition timeline for publication in the American Journal of Medical Genetics has changed. The updated diagnostic criteria for hEDS and several monogenic types will now be released in the second paper slated for publication in March/April 2027. The special edition will now be published in two parts:

Part 1: December 2, 2026

  • A review and update of the 2017 International Classification.
  • Assessment and guidance for cEDS and vEDS.
  • Information on the process towards developing a diagnostic framework for hEDS and HSD.

Part 2: March/April 2027

  • The updated diagnostic criteria for hEDS and HSD.
  • Assessment and guidance for hEDS and HSD, and a diagnostic pathway covering all types of EDS and HSD. 
  • Assessment and guidance for the other monogenic types of EDS.

While this is disappointing news for the EDS community that has been anxiously awaiting new diagnostic guidelines in the hope that they would lead to more validation and improve access to care, Dr Clair Francomano explains that “There was always too much to put into one publication, so the decision was made to focus on the monogenic types in the first edition. I hate that this has caused more anxiety for patients, but science is evolving quickly and we want to get this right.” Dr Francomano also acknowledged that she understands patient frustration and reinforced that “nobody is going to lose their diagnosis.” The EDS Society has stated that people who already have a diagnosis do not need to be re-evaluated and that clinicians can continue using the 2017 diagnostic criteria until they are updated. 

It is not uncommon for publication dates to slide, as peer review is a critically important part of scientific rigor. But for a community that has been holding hope all year and following the Society’s highly branded countdown campaign, this news that patients must wait another three months is understandably disappointing as there is so much riding on it. People with hEDS, people with HSD, and people with the rare genetic types are each waiting for the criteria with their own needs and concerns, and not all of those hopes point in the same direction.

One Update, Many Goals

For people living with hEDS, the hope is that the new criteria will finally fit the condition they actually live with. The 2017 criteria focused heavily on joint hypermobility and were considered “too narrow” because they did not acknowledge the multi-system, co-occurring conditions that make daily life hard, such as digestive problems, dysautonomia, and neurological conditions.  The Norris Lab at the Medical University of South Carolina has contended that “diagnostic criteria must better reflect the multisystem nature of hEDS and HSD.” Patients and advocates such as Jon Rodis, founder of The Connective Tissue Coalition, wholeheartedly agree. Jon is well known in EDS circles, as he has been in the trenches supporting patients for over twenty years. His phone rings seven days a week with people suffering greatly and trying to get effective medical help. Jon explains, “It is imperative that the new criteria address the many comorbid conditions that are part of hEDS and are backed up by high-level research and the valuable patient perspective/experience. There is no longer room for lower-level science.”

For people living with HSD, the hope is more focused on recognition. HSD was created in 2017 for people with symptomatic hypermobility who didn’t meet the full hEDS criteria. For many, it has felt like a lesser label and unfortunately it has caused more clinical confusion within the medical community that has not given it proper attention, even though people categorized as having HSD can have the same severe comorbid conditions as people diagnosed with hEDS. It is a problem that was discussed at the University of Virginia (UVA) EDS Symposium in April, as EDS Society President Lara Bloom explained that in parts of Europe, “you’re not getting any care if you’ve got a diagnosis of HSD.” Evolving research suggests that hEDS and HSD sit on a shared spectrum and there has been much speculation that the two conditions may indeed be blended into one. 

The Added Challenges of Rare and Monogenetic

For people living with the rare genetic types, such as Vascular, Classical, Myopathic or Kyphoscoliotic EDS (to name just a few), the stakes are quite different. These types have known genetic causes and can be confirmed with a test. Some carry serious or life-threatening complications affecting blood vessels and organ systems. Although there is a clearer path to diagnosis for people living with the rarer monogenetic types, these patients also face much higher stakes when it comes to treatment, misdiagnosis and improper care. 

Abbey Phillipson, one of the founders of The Collagen Advocacy Network, a newly established nonprofit organization dedicated to education, support and research for rare and ultra-rare forms of EDS, believes that the rare forms would be better served if they could be completely separated under the new classification and come out from under the umbrella of EDS. 

This young advocate gave a mic-dropping presentation at the University of Virginia EDS Symposium in April, explaining that people living with rare and ultra-rare types of EDS are actually experiencing added harm because clinicians often approach their medical care through the lens of hEDS and HSD, a problem that she believes is one of priority. 

The Collagen Advocacy Network has put out patient surveys that support her request to remove the rare types from the EDS umbrella and name each condition by its gene and predominant manifestation, something she sees as an important opportunity to improve medical clarity and safety in care. The big question is, does the International Consortium defining the new criteria agree? 

“Many of us would prefer to be orphaned,” Phillipson explained, as the designation could allow the monogenic types to qualify for more opportunities with rare disease funding. “The ultra-rare EDS types make up only about 1 to 3 percent of the community and are frequently left out of decisions about research, funding, and care.” 

If the new criteria do not separate out the monogenic types, then Phillipson has another burning question on her mind: “If we don’t get separation, or new nomenclature, then what does the Society plan to do differently to better protect people living with rarer forms?” 

It is a question that people worldwide living with the monogenic types hope will be answered soon. 

Neuro-EDS and the Future of EDS Classification

So as the community awaits the release of the updated diagnostic criteria, a group of pioneering physicians introduced a new idea to the conversation when neurosurgeon Dr Paolo Bolognese and Dr Allison Bloom proposed a different framework at the 2026 EDS Society Conference in Texas called “Neuro-EDS”. Their manuscript, Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders, authored by several highly experienced physicians, attempts to describe what they believe is a new phenotype, a subgroup of patients with hEDS and HSD whose illness is neurological. It is an interesting approach that seeks to identify patient groups by body parts most affected, and could radically change the way that clinicians group symptoms, evaluate patients and approach care, as well as how researchers design studies. 

  • Cranial and spinal: craniocervical instability, Chiari, tethered cord, cerebrospinal fluid pressure problems and leaks, venous outflow problems, Eagle syndrome.
  • Neuro-autonomic-inflammatory: POTS and dysautonomia, mast cell activation, small fiber neuropathy, gut dysmotility, cognitive problems, ME/CFS-like fatigue.

Dr Bloom and Dr Bolognese recently presented this exciting new framework on the Chronic Pain Partners, EDS Awareness Educational Webinar. 

It should be noted that Neuro-EDS is not a new disease or a new EDS type, but it will be interesting to see if the Society adopts the concept or includes it in upcoming publications. Patient response has been highly positive since complex neurological symptoms can be extremely difficult to diagnose, and finding doctors willing to treat them can be a challenge. German disability advocate Karina Sturm explains, “It could really help patients who are wrongly labeled as psychosomatic and give people access to better care. This is especially important in countries outside the US where healthcare systems do not even recognize craniocervical instability, and only a few doctors spread across Europe provide care.”

From Now Until Spring

For patients who are suffering and silently fighting for validation and better care, it is understandable that the uncertainty of not knowing what will be published this spring feels heavy, and the extended wait time more stressful. But classifying a disease, especially one that is multi-systemic, is a herculean task that must follow strict scientific guidelines and processes. 

And in spite of all that we don’t yet know, it is even more important to hold onto what we do know. The clinical confusion of the 2017 criteria is being addressed, and this will hopefully create new opportunities for validation, access to better care, and better days ahead for patients and clinicians alike. 

Go Science!

DM Sullivan
Producer, Complicated 
Founder & Executive Director, Elevate Rare
November, 2026



Sources: Forghani I, See J, McGonigle WC. “Hypermobile Ehlers–Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.” Genes (Basel). 2025 Apr 29;16(5):530. doi:10.3390/genes16050530


If you like what you read, please comment and share!

5 Responses to “What’s Actually Happening With the New EDS Diagnostic Criteria?”

  1. Dena says:

    What an exciting time for EDS research! Thank you so much, Donna and Chronic Pain Partners, for always keeping us in the loop and updated on what’s happening in the EDS world. We are so lucky to have you and we appreciate you! ❤️🦓

  2. Marjon ten Hove says:

    Thanks for this overview. I don’t think it’s just to only call it higher stakes for the (ultra)rare types because (only) they can be lethal… At least, here in The Netherlands people (and I) with hEDS are dying because of no access to care when having severe gut motility disorders….
    Please we exist too, at least we hold on for now

    1. jteti says:

      Hi Marjon,
      Thank you for raising this. You’re right that the stakes can be very high for people with hEDS and HSD too, particularly when appropriate care is unavailable. The passage was intended to highlight the specific risks associated with some rarer EDS types. We also recognize how severely people with hEDS and HSD can be affected, and how devastating barriers to care can be. Thank you for sharing your experience and drawing attention to this.

  3. Maggie says:

    Very grateful for the update!

    1. jteti says:

      So glad you found this helpful!

Leave a Reply